Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

• DOI: 10.1111/all.14680
• Publication Date: 2020-12-01T09:10:02Z
• Authors: William R. Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J. Longhurst; Marc A. Riedl; Hannah B. Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
• Keywords: Hereditary Angioedema; Discontinuation

Abstract Background An objective of the phase 3 HELP Study was to investigate effect lanadelumab on health‐related quality life (HRQoL) in patients with hereditary angioedema (HAE). Methods Patients HAE‐1/2 received either 150 mg every 4 weeks (q4wks; n = 28), 300 q4wks ( 29), 2 (q2wks; 27), or placebo 41) for 26 (days 0–182). The Angioedema Quality Life Questionnaire (AE‐QoL) administered monthly, consisting four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores. generic EQ‐5D‐5L questionnaire days 0, 98, 182. Comparisons were made between (a) all lanadelumab‐treated (b) individual groups changes scores (day 0–182) proportions achieving minimal clinically important difference (MCID, −6) AE‐QoL score. Results Compared group, group demonstrated significantly greater improvements (mean change, −13.0 −29.3; p < 0.05 all); largest improvement functioning. A proportion achieved MCID (70% vs 37%; 0.001). q2wks had highest (81%; 0.001) 7.2 times more likely achieve than group. Mean at day 0 high groups, indicating low impairment, no significant Conclusion experienced meaningful HRQoL measured by following treatment Study.